Skip to main content

Security report for aktisoncology.com

Aktis Oncology · Healthcare · N/a

Medium risk. 7 critical or high findings in Security headers, GDPR outside view and 2 other checks.

Security score

59/100

Risk levelMedium

0–100, higher is better. How it is calculated

Aktis Oncology is a biotechnology company specializing in the development of alpha radiopharmaceuticals aimed at revolutionizing cancer care by delivering targeted alpha-emitting drugs. The company positions itself as an innovator in precision oncology, focusing on solid tumors with limited current treatment options. Their website reflects a professional and modern digital presence built on WordPress, leveraging SEO and marketing tools such as Yoast SEO and Mailchimp. The site is well-structured, mobile-optimized, and provides clear navigation and content relevant to their business domain. Security-wise, the website enforces HTTPS and uses secure forms but lacks some advanced security headers and explicit security policies. The absence of WHOIS data for the domain raises some concerns about domain registration transparency, although the website content and branding are consistent with a legitimate healthcare business. Overall, the site demonstrates a good level of digital maturity but could improve privacy compliance and security disclosures.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

Need hands-on remediation? Email guard@offseq.com

Keep watching aktisoncology.com

This scan found 27 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
15
Email security
50
DNS health
65
Network security
100
GDPR outside view
53
Average
59

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Aktis Oncology operates in the healthcare biotechnology sector, focusing on novel cancer therapies using alpha radiopharmaceuticals. Their business model centers on research and development of targeted cancer treatments, likely generating revenue through partnerships, licensing, or direct product commercialization. The company targets a broad audience including healthcare professionals, investors, and potential employees. Their market position is that of an emerging innovator with a specialized therapeutic focus. The website indicates a small-sized company founded around 2021, with no parent or subsidiary companies disclosed. The presence of a careers page suggests growth ambitions. The company maintains a LinkedIn presence, supporting professional networking and brand visibility. The lack of direct contact emails or phone numbers suggests controlled communication channels, typical for biotech firms.

Security posture

The website demonstrates a moderate to good security posture with HTTPS enabled and secure form handling. However, it lacks visible security headers such as Content-Security-Policy and X-Frame-Options, which are recommended best practices. There is no published security policy or incident response contact information, which limits transparency and preparedness perception. No vulnerabilities or exposed sensitive data were detected in the HTML content. The absence of a cookie consent mechanism and limited privacy compliance indicators suggest room for improvement in regulatory adherence, especially GDPR. The WHOIS data absence reduces trust in domain legitimacy. Overall, the security posture is adequate for a corporate website but should be enhanced to meet higher compliance and security standards.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  2. Add a cookie consent banner and detailed cookie policy to improve GDPR compliance.
  3. Publish a dedicated security policy and incident response contact information to enhance transparency.
  4. Regularly audit and update WordPress plugins and themes to mitigate vulnerabilities.
  5. Investigate and resolve the absence of WHOIS data to improve domain registration transparency and trust.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Aktis Oncology
Description
Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care
Key services
design and development of alpha-emitting radiopharmaceutical drugs, cancer treatment innovation
Content quality
excellent
Branding
consistent

Technology

Stack
WordPress, Yoast SEO plugin, jQuery, Bootstrap 4.6, Mailchimp for WordPress, Contact Form 7, Sassy Social Share
Frameworks
Genesis Framework (WordPress theme)
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • No exposed sensitive data in HTML
  • Secure contact forms

Analytics and tracking

Services
Google Analytics (via Google Tag Manager)
Tracking level
moderate
Privacy practices
basic

Advertising

Marketing tools
Mailchimp, Sassy Social Share
Transparency
basic

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Professional biotechnology company site focused on alpha radiopharmaceuticals.
  3. Uses WordPress CMS with modern plugins and SEO optimization.
  4. No direct company contact emails or phone numbers found; contact via form only.
  5. Privacy and terms pages present but no cookie consent mechanism detected.
  6. No explicit security policy or incident response information found.
  7. WHOIS data unavailable, which impacts domain legitimacy assessment.
  8. Social media presence limited to LinkedIn link.
  9. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on WordPress CMS using the Genesis Framework and several popular plugins such as Yoast SEO, Contact Form 7, Mailchimp for WordPress, and Sassy Social Share. It uses Bootstrap 4.6 for responsive design and jQuery for client-side scripting. Google Tag Manager is implemented for analytics and marketing tracking. The site is mobile-optimized with good accessibility features and SEO meta tags including Open Graph and JSON-LD structured data. Performance is moderate with no obvious blocking scripts or heavy resources. Hosting provider details are not disclosed. The technical stack is modern and appropriate for a small to medium-sized biotech company website, with opportunities to enhance security and privacy features.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with aktisoncology.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review aktisoncology.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.